van Maldegem, A. M., Benson, C., Rutkowski, P., Blay, J. Y., van den Berg, H., Placzke, J., Rasper, M., Judson, I., Juergens, H., Dirksen, U., Gelderblom, H. (2015) Etoposide and Carbo-or Cisplatin Combination Therapy in Refractory or Relapsed Ewing Sarcoma: A Large Retrospective Study. PEDIATRIC BLOOD & CANCER, 62 (1). pp. 40-44. ISSN 1545-5009

Full text not available from this repository.

Abstract

BackgroundPatients with Ewing sarcoma (EWS) who develop refractory or relapsed disease have limited treatment options. In some sarcoma centres in Europe the combination of etoposide with carbo- or cisplatin is being used for these patients, however, there are no published data available yet. Here we investigated the outcome of the combination treatment for patients with advanced Ewing sarcoma in progression after standard treatment. ProcedureAll patients diagnosed with EWS between 1980 and 2012 in one of six major sarcoma centres in Europe and treated with either carboplatin and etoposide or cisplatin and etoposide were included and data were retrospectively collected for analysis. ResultsA total of 107 patients enrolled in this study of which 61 received the combination of etoposide and carboplatin and 46 received etoposide and cisplatin. The median overall survival (OS) was 23 months for both patient groups and the 5-year OS was 24.5% for the patients who received carboplatin and etoposide and 20% for those who received cisplatin and etoposide. The progression free survival was better in patients treated with the combination of carboplatin and etoposide (14.5 vs. 6.3 months P=0.023). ConclusionThis is a retrospective study on the combination treatment of etoposide and carbo- or cisplatin in refractory Ewing sarcoma. The results justify exploring the combination in a prospective study with relapsed patients. Pediatr Blood Cancer 2015;62:40-44. (c) 2014 Wiley Periodicals, Inc.

Item Type:	Article
Authors (ICR Faculty only):	Judson, Ian
All Authors:	van Maldegem, A. M., Benson, C., Rutkowski, P., Blay, J. Y., van den Berg, H., Placzke, J., Rasper, M., Judson, I., Juergens, H., Dirksen, U., Gelderblom, H.
Additional Information:	ISI Document Delivery No.: AU0NG Times Cited: 0 Cited Reference Count: 27 van Maldegem, Annemiek M. Benson, Charlotte Rutkowski, Piotr Blay, Jean-Yves van den Berg, Henk Placzke, Joanna Rasper, Meybrit Judson, Ian Juergens, Heribert Dirksen, Uta Gelderblom, Hans 0 WILEY-BLACKWELL HOBOKEN PEDIATR BLOOD CANCER
Uncontrolled Keywords:	etoposide Ewing sarcoma outcome platinum prognostic factor retrospective CELL LUNG-CANCER RANDOMIZED PHASE-II THORACIC RADIOTHERAPY PEDIATRIC SARCOMAS PROGNOSTIC-FACTORS YOUNG-ADULTS TUMORS GEMCITABINE DOCETAXEL CARBOPLATIN
Research teams:	ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) Clinical Units > Sarcoma Unit ICR divisions > Clinical Studies > Sarcoma Clinical Trials
Depositing User:	Barry Jenkins
Date Deposited:	08 Jan 2015 16:03
Last Modified:	08 Jan 2015 16:03
URI:	http://publications.icr.ac.uk/id/eprint/13803

Actions (login required)

View Item